 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...160161162163164165166167168169170...208209» |
- || edralbrutinib (TG-1701) / TG Therap
Trial completion, Trial completion date: Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin) (clinicaltrials.gov) - Jan 10, 2021
P1, N=20, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Mar 2021 --> Dec 2020
- ||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
Journal, Adverse events: Expert consensus on the management of adverse events of ErbB family tyrosine kinase inhibitors in breast cancer (Pubmed Central) - Jan 9, 2021
The Breast Cancer Expert Group of Chinese Society of Clinical Oncology (CSCO) summarized the incidence and characteristics of AEs of TKI, evaluated the manifestations and severity of AEs, and formulated the consensus of the management of common AEs based on the clinical experiences and updated advances from domestic and abroad studies. This consensus aims to provide the practical strategy for clinicians in the management of ErbB-family TKI-related AEs in China, and eventually enhance the patients' compliance and improve the therapeutic efficacy.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib-Induced Multiple Organ Hemorrhage: A Case Report. (Pubmed Central) - Jan 9, 2021
This consensus aims to provide the practical strategy for clinicians in the management of ErbB-family TKI-related AEs in China, and eventually enhance the patients' compliance and improve the therapeutic efficacy. No abstract available
- | Journal: Conformational landscapes of HER2 exon 20 insertions explain their sensitivity to kinase inhibitors in lung adenocarcinoma. (Pubmed Central) - Jan 9, 2021
Kinase conformational landscape dictated by the length of αC-β4 loop and residues at HER2 776 and 778 position explains TKI sensitivity in ex20ins. This finding could guide therapeutic decisions with currently available therapies and future drug development strategies.
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical, Journal: Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer. (Pubmed Central) - Jan 8, 2021
Pyrotinib-based therapy demonstrates promising efficacy for HER2-positive advanced solid tumors excluding breast cancer and toxicities could be well controlled. The study is a pilot study motivating larger studies to elucidate the safety and efficacy of pyrotinib in non-breast solid tumors.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. (Pubmed Central) - Jan 8, 2021
PIB effectively targeted apatinib to HCC tissues, achieved a slow and sustained release of the drug in the tumor and considerably reduced the systemic drug concentration. Further experiments showed significantly prolonged survival times and an inhibitory effect on tumor growth.
- | ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
Enrollment status: Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment (clinicaltrials.gov) - Jan 7, 2021
P1, N=24, Enrolling by invitation, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Further experiments showed significantly prolonged survival times and an inhibitory effect on tumor growth. Recruiting --> Enrolling by invitation
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, New P4 trial, IO biomarker: Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov) - Jan 7, 2021
P4, N=30, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- || Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P1 trial: A Trial of SHR8735 in Healthy Subjects (clinicaltrials.gov) - Jan 7, 2021
P1, N=48, Not yet recruiting, Sponsor: Atridia Pty Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Retrospective data, Journal: Efficacy and safety of apatinib as third- or further-line therapy for patients with advanced NSCLC: a retrospective study. (Pubmed Central) - Jan 7, 2021
In contrast, there were no differences in adverse reactions between the patients in the treatment and control groups. Apatinib showed favourable efficacy and safety and can thus be used as a treatment option for patients with advanced NSCLC.
- |||| HR021618 / Jiangsu Hengrui Pharma
New P2 trial, Surgery: A Trial of HR021618 in Postsurgical Pain Management (clinicaltrials.gov) - Jan 6, 2021
P2, N=108, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: SHR-1701-?-206: A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC (clinicaltrials.gov) - Jan 6, 2021
P2, N=168, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Stivarga (regorafenib) / Bayer
[VIRTUAL] Study on Regorafenib Combined with Transcatheter Arterial Chemoembolization in the Treatment of Advanced Hepatocellular Carcinoma after First Line Targeted Therapy () - Jan 6, 2021 - Abstract #DLCS2021DLCS_50;
The 3 and 6 month progression free survival rate (PFSR) was 92.7%. and 81.3% respectively.
- | Conmana (icotinib) / Betta
Journal: Dual Loading of Nanoparticles with Doxorubicin and Icotinib for the Synergistic Suppression of Non-Small Cell Lung Cancer. (Pubmed Central) - Jan 6, 2021
EDS NPs significantly promoted the in vivo synergistic effects of icotinib and DOX in the mouse model. The study suggests that EDS NPs possess noteworthy potential for development as therapeutics for NSCLC clinical chemotherapy.
- | Opdivo (nivolumab) / Ono Pharma, BMS
Retrospective data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker: A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. (Pubmed Central) - Jan 6, 2021
ICI-associated myocarditis is a rare adverse event but has a high mortality rate. Early diagnosis of myocarditis and prompt glucocorticoid therapy may be helpful to improve the prognosis.
- ||| dexmedetomidine nasal spray / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults (clinicaltrials.gov) - Jan 6, 2021
P2/3, N=108, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Early diagnosis of myocarditis and prompt glucocorticoid therapy may be helpful to improve the prognosis. Trial completion date: Oct 2020 --> May 2021 | Trial primary completion date: Sep 2020 --> May 2021
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion: AIAC: Apatinib for Inoperable Advanced Chondrosarcoma (clinicaltrials.gov) - Jan 5, 2021
P=N/A, N=40, Completed, Sponsor: Peking University People's Hospital
Trial completion date: Oct 2020 --> May 2021 | Trial primary completion date: Sep 2020 --> May 2021 Active, not recruiting --> Completed
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer (clinicaltrials.gov) - Jan 4, 2021
P2, N=60, Not yet recruiting, Sponsor: Quan Wang
- || AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P1 trial: Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function (clinicaltrials.gov) - Jan 4, 2021
P1, N=24, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. (Pubmed Central) - Jan 3, 2021
P=N/A
Apatinib showed promising efficacy and an acceptable safety profile in patients with advanced AFPGC. Antiangiogenic therapy may be a good strategy for the treatment of AFPGC as a rare sub-type of gastric cancer.
- | Journal: Characterization of covalent binding of tyrosine kinase inhibitors to plasma proteins. (Pubmed Central) - Jan 2, 2021
The covalent binding is of species difference, especially between animal and human. Except for osimertinib, covalent binding between TKIs and HSA are reversible.
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical, Journal, Tumor Mutational Burden, IO biomarker: Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies. (Pubmed Central) - Jan 1, 2021
TMB exhibited more power than ERBB2 CNV in predicting treatment responses and prognosis for HER2-targeted therapy in GC patients. Interestingly, survival analysis indicated that patients harboring both HER2 (ERBB2) positivity and high TMB might gain more therapeutic benefits from immune checkpoint inhibitors instead of HER2-targeted regimens that required further studies and validations Our work showed that the dynamic surveillance of plasma ctDNA genomic features provided instructive information for the precision medication of GC patients.
- | Xalkori (crizotinib) / Pfizer
Journal: Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study. (Pubmed Central) - Jan 1, 2021
The results of the study showed that the main target organs of crizotinib were the lung, liver, and spleen, and a high concentration of crizotinib was found in the gastrointestinal tract. This study offers a reliable method for quantifying crizotinib and provides a basis for further research on crizotinib toxicity.
- || SHR-1819 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of SHR-1819 in Healthy Subjects (clinicaltrials.gov) - Dec 30, 2020
P1, N=42, Recruiting, Sponsor: Atridia Pty Ltd.
This study offers a reliable method for quantifying crizotinib and provides a basis for further research on crizotinib toxicity. Not yet recruiting --> Recruiting
- |||||||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. (clinicaltrials.gov) - Dec 30, 2020
P3, N=486, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P3 trial: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 30, 2020
P3, N=804, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || edralbrutinib (TG-1701) / TG Therap
Enrollment closed: Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin) (clinicaltrials.gov) - Dec 30, 2020
P1, N=20, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Preclinical, Journal: Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model. (Pubmed Central) - Dec 30, 2020
Compared with monotherapy treatment, combined treatment better resisted angiogenesis. Apatinib combined with radiotherapy to treat nasopharyngeal carcinoma has synergistic effects, which may be related to enhanced antiangiogenesis.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date: Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 30, 2020
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
Apatinib combined with radiotherapy to treat nasopharyngeal carcinoma has synergistic effects, which may be related to enhanced antiangiogenesis. Trial completion date: Jun 2022 --> Jun 2024
- | AiTan (rivoceranib) / HLB Bio Group
New trial, Real-world evidence, Real-world: Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma (clinicaltrials.gov) - Dec 29, 2020
P=N/A, N=79, Active, not recruiting, Sponsor: Peking University People's Hospital
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. (Pubmed Central) - Dec 29, 2020
Furthermore, 13 patients achieved stable disease and 10 patients had progressive disease, and accordingly, the disease control rate was 72.7%. In conclusion, apatinib plus S-1 for advanced solid tumor patients as palliative treatment have a certain efficacy and was relatively safe but should be used with caution in patients with squamous-cell lung carcinoma and the efficacy and safety requires further assessment.
- | AiTan (rivoceranib) / HLB Bio Group
Preclinical, Journal: Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo. (Pubmed Central) - Dec 29, 2020
Apatinib showed no obvious effects on body mass of models and did not affect function of important organs, except for occasional focal lymphoid infiltration of liver (16.7%) and cardiac muscle (16.7%). We successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer (clinicaltrials.gov) - Dec 28, 2020
P2, N=100, Not yet recruiting, Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
We successfully established MPM PDX models and primary cell lines, and confirmed that apatinib effectively inhibited proliferation and metastasis of MPM in vitro and in vivo study. N=57 --> 100 | Trial completion date: May 2023 --> Aug 2024 | Initiation date: May 2020 --> Feb 2021 | Trial primary completion date: May 2021 --> Oct 2023
- || AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
Enrollment closed: A Phase II Study in Patients With Alopecia Areata (clinicaltrials.gov) - Dec 28, 2020
P2, N=80, Active, not recruiting, Sponsor: Reistone Biopharma Company Limited
N=57 --> 100 | Trial completion date: May 2023 --> Aug 2024 | Initiation date: May 2020 --> Feb 2021 | Trial primary completion date: May 2021 --> Oct 2023 Recruiting --> Active, not recruiting
- ||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P1 trial: Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations (clinicaltrials.gov) - Dec 28, 2020
P1, N=58, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| PD-1 list: Keytruda, Opdivo, Tecentriq, and Imfinzi are out of this game, unfortunately. Camrelizumab (Hengrui), Toripalimab (Junshi), Tislelizumab (BeiGene), and Sintilimab （Innovent） have made it. (Twitter) - Dec 28, 2020
- ||| retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Enrollment open: SHR-1701-II-204: A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer (clinicaltrials.gov) - Dec 27, 2020
P1/2, N=54, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, poziotinib (HM 78136B) / Spectrum, Hanmi, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
not very impressive, similar to pyrotinib. ORR 28% similar to pyrotinib, ORR 62% about with DS-8201a. PFS 5-7 months with pyrotinib and poziotinib, 14 months with DS-8201a. All of these are small cohorts, but pozi definitely does not look like best of the bunch (Twitter) - Dec 24, 2020
- | eribulin mesylate / Generic mfg.
New trial, Real-world evidence: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer (clinicaltrials.gov) - Dec 23, 2020
P, N=80, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC (clinicaltrials.gov) - Dec 23, 2020
P2, N=69, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | AiTan (rivoceranib) / HLB Bio Group
Biomarker, Journal, Tumor microenvironment, PD(L)-1 Biomarker: Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer. (Pubmed Central) - Dec 23, 2020
Not yet recruiting --> Recruiting Our results suggested that the tumor microenvironment could be managed with apatinib, which was effective in eliciting an abscopal effect induced by SABR.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Anlotinib in treatment of an elderly patient with recurrent advanced SCLC. (Pubmed Central) - Dec 23, 2020
The patient was given chemotherapy again, with albumin-bound paclitaxel, etoposide capsules, apatinib, and other treatment...This is the first report on the precise efficacy of anlotinib in the treatment of advanced small cell lung cancer. Anlotinib is an important option for patients with small cell lung cancer.
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells. (Pubmed Central) - Dec 23, 2020
Further, we found that apatinib could directly act on tumor cells and promote ROS-dependent apoptosis and autophagy. Mechanistically, we showed that apatinib suppressed glutathione to generate ROS via the downregulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway and maintained an antitumor effect at a low level of VEGFR2 in ovarian cancer, suggesting that combination of apatinib with Nrf2 inhibitor may be a promising therapy strategy for patients with ovarian cancer.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract (clinicaltrials.gov) - Dec 22, 2020
P2, N=40, Recruiting, Sponsor: Fudan University
Mechanistically, we showed that apatinib suppressed glutathione to generate ROS via the downregulation of the nuclear factor erythroid 2-related factor 2 (Nrf2)/heme oxygenase 1 (HO-1) pathway and maintained an antitumor effect at a low level of VEGFR2 in ovarian cancer, suggesting that combination of apatinib with Nrf2 inhibitor may be a promising therapy strategy for patients with ovarian cancer. Not yet recruiting --> Recruiting
- ||| AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
Enrollment open: A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer (clinicaltrials.gov) - Dec 22, 2020
P1, N=74, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | New trial, Checkpoint inhibition: Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study (clinicaltrials.gov) - Dec 22, 2020
P, N=400, Recruiting, Sponsor: Sun Yat-sen University
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
New trial: FINESTdm: Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib (clinicaltrials.gov) - Dec 22, 2020
P, N=200, Recruiting, Sponsor: Wuhan Union Hospital, China
- ||||| AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Study of SHR-1210 (clinicaltrials.gov) - Dec 22, 2020
P2, N=250, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
New P2 trial: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 22, 2020
P2, N=71, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC (clinicaltrials.gov) - Dec 22, 2020
P2, N=30, Recruiting, Sponsor: Sun Yat-sen University